Amgen has set its sights on Coherus Biosciences, a biosimilar maker, for allegedly infringing a patent concerning a process for purifying proteins.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Amgen, patent, patent infringement, Coherus Biosciences, Neulasta, Biologics Price Competition and Innovation Act, biologics, biosimilars